BioAtla Results Presentation Deck

● Significant Unmet Need and Commercial Opportunity Across Multiple Solid Tumors Types • ~17K newly diagnosed metastatic cases / yr (US) ● Sarcoma 5-year survival rate (~20% for advanced metastatic disease) UPS is one of the largest and most aggressive sarcoma subtypes Osteosarcoma represents nearly 1/3 of all bone sarcoma cases aggressive tumors - high recurrence - with limited treatment options ● NSCLC ~200K newly diagnosed NSCLC patients/yr (US) J 5-year survival rate (~25% for advanced metastatic disease) • While relatively crowded market, there is a lack of efficacious therapies for refractory patients Sources: www.cancer.net; www.cancer.org; Clarivate, Disease Landscape and Forecast: NSCLC, Melanoma, SCCHN (2022) Melanoma ● ~200K newly diagnosed cases / yr (US) - 50% invasive • 5-year survival rate (~25% for advanced metastatic disease) ~1.3mm people in the US living with melanoma Head & Neck • ~66K newly diagnosed cases / yr (US) ● ● bicatla 5-year survival rate (~40% for recurrent or advanced metastatic disease) Deficit of 2nd line treatments 9

View entire presentation